Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)

NCT00310830 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

14

Enrollment

INDUSTRY

Sponsor class

Stopped Slow enrollment

Conditions

Pulmonary Hypertension

Interventions

DRUG: Bosentan

Sponsor

Actelion